Cabot (CBT) Q4 2026 Earnings Call Transcript

Cabot reported fiscal Q4 2026 adjusted EPS of $1.61 and sales of $1.009 billion; operating income was $121 million versus $137 million a year earlier. Fiscal 2027 adjusted EPS guidance is $6.15–$6.75 amid flat tire-production expectations and ongoing customer negotiations, while Performance Chemicals EBIT rose 43% year over year to $60 million. Full-year operating cash flow was $421 million, and Cabot returned $243 million to shareholders; it plans $200–$230 million in fiscal 2027 capital spending, including battery-materials capacity investments expected to support higher growth in fiscal 2028.

Analysis

CBT’s key near-term valuation risk is not weak aggregate tire demand alone, but the conversion of customer negotiations into gross profit per ton and share retention. With only about one-third of 2027 agreements concluded, the EPS range embeds an unresolved commercial outcome; lower tire imports in North America and Europe are not yet translating into stronger local production, while South American imports add pressure. That leaves limited evidence for a quick Reinforcement Materials recovery. Performance Chemicals is a useful earnings buffer, but battery EBITDA is guided only modestly higher in FY27 as capacity start-up costs precede the expected FY28 contribution. The AI/CMP exposure is a credible multi-year growth lever, not yet enough to offset a weak tire-contract outcome on its own.

Near term (days to weeks), expect the market to focus on the EPS range and negotiation uncertainty rather than annual cash generation. Over 1–3 months, completed tire agreements and Q1 segment EBIT are the principal catalysts. Over 6–18 months, battery capacity ramp, electronics growth, and the ability to monetize North American/European trade measures matter more. Contrarian point: trade barriers could eventually redirect tire production toward regional suppliers, but imports falling without production recovering shows that the demand response may be slow; treating tariff effects as an imminent earnings tailwind is premature. Capex and working-capital needs also compete with buybacks, though stated liquidity and leverage provide a buffer.

Key Decisions for Investors

• Stay neutral-to-underweight CBT ahead of the remaining 2027 tire negotiations; avoid paying for a rapid Reinforcement Materials rebound. Reassess when most agreements are settled and management provides evidence of stable or improving gross profit per ton.
• For existing CBT exposure, consider a defined-risk downside hedge through the negotiation window rather than an outright short: the Performance Chemicals franchise and cash generation limit the case for an unhedged bearish position. No price target is warranted from the supplied information.
• Track Q1 Reinforcement Materials EBIT versus the company’s expectation for a modest sequential improvement, and Performance Chemicals EBIT versus the stated sequential $6–8 million cost/mix headwind. A miss in both would weaken the earnings-buffer thesis; better-than-guided results would support a more constructive stance.
• Treat battery and AI-linked electronics as a FY28-and-beyond catalyst, not a FY27 earnings substitute. Verify capacity commissioning, customer volumes, and incremental returns before underwriting stronger growth; rising start-up costs without subsequent volume growth would falsify the investment thesis.